MicroRNAs Regulation of Axon Sprouting in Peripheral Nerve Regeneration: A Systematic Review.

Mol NeurobiolOct 1, 2026 (epub)
Clinical ResearchNeurologyPhysical Medicine & RehabilitationOpen access

Elahe Khademi, Mohammad Reza Nourani, Ali Najafi

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examines the role of microRNAs (miRNAs) in peripheral nerve regeneration, focusing on miR-21, miR-133b, miR-124, and miR-30b. It highlights their influence on axonal sprouting and critical signaling pathways. Preclinical studies indicate that miRNA-loaded exosomes can enhance neurite outgrowth and functional recovery in sciatic nerve injury models.

Key findings

  • miR-21, miR-133b, miR-124, and miR-30b are key regulators of axonal sprouting.
  • miRNA-loaded exosomes can enhance neurite outgrowth in preclinical models.
  • Targeted delivery systems for miRNAs include viral vectors and polymeric nanoparticles.
  • Challenges in miRNA delivery and specificity hinder clinical translation.

Why it matters

Understanding the role of miRNAs in nerve regeneration could lead to innovative therapeutic strategies for improving recovery after peripheral nerve injuries, which often result in significant functional deficits.

Source

PubMed · PMID 42821019Free full text on PubMed Central

Published in Mol Neurobiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.